Abstract
Imbalance in prefrontal cortical (PFC) pyramidal neuron excitation:inhibition is thought to underlie symptomologies shared across stress-related disorders and neuropsychiatric disease, including dysregulation of emotion and cognitive function. G protein-gated inwardly rectifying K+ (GIRK/Kir3) channels mediate excitability of medial PFC pyramidal neurons, however, the functional role of these channels in mPFC-dependent regulation of affect, cognition, and cortical dynamics is unknown. We used a viral-cre approach in male and female mice harboring a “floxed” version of the kcnj3 (Girk1) gene, to disrupt GIRK1-containing channel expression in pyramidal neurons within the prelimbic cortex (PrL). In males, loss of pyramidal GIRK1-dependent signaling differentially impacted measures of affect and impaired working memory and cognitive flexibility. Unexpectedly, ablation of PrL GIRK1-dependent signaling did not impact affect or cognition in female mice. Additional studies used a model of chronic unpredictable stress (CUS) to determine the impact on PrL GIRK-dependent signaling and cognitive function. CUS exposure in male mice produced deficits in cognition that paralleled a reduction in PrL pyramidal GIRK-dependent signaling akin to viral approaches whereas CUS exposure in female mice did not alter cognitive flexibility performance. Stress-induced behavioral deficits in male mice were rescued by systemic injection of a novel, GIRK1-selective agonist, ML297. In conclusion, GIRK1-dependent signaling in male mice, but not females, is critical for maintaining optimal PrL function and behavioral control. Disruption of this inhibition may underlie stress-related dysfunction of the PrL and represent a therapeutic target for treating stress-induced deficits in affect regulation and impaired cognition that reduce quality of life.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 2158-2169 |
| Number of pages | 12 |
| Journal | Neuropsychopharmacology |
| Volume | 46 |
| Issue number | 12 |
| Early online date | Jun 23 2021 |
| DOIs | |
| State | Published - Nov 2021 |
Bibliographical note
Funding Information:These studies were supported by funding from the Brain and Behavior Research Foundation (#26299; MH), Marquette University Regular Research Grant (MH), the Charles E Kubly Mental Health Research Foundation at Marquette University (MH), and NIH grants DA034696 and AA027544 (KW). The authors have no biomedical financial interests or potential conflicts of interest.
Publisher Copyright:
© 2021, The Author(s), under exclusive licence to American College of Neuropsychopharmacology.